Oops! CRISPR Concerns Turn Out to be a Big Nothingburger – Motley Fool
Wall Street Morning |
Oops! CRISPR Concerns Turn Out to be a Big Nothingburger
Motley Fool You might have thought last year that the curtains were closing on a promising gene-editing therapy called CRISPR-Cas9. An article in Nature Methods published in May 2017 suggested that CRISPR-Cas9 could have serious drawbacks. The news caused the … Analysts recommended an average rating score of 2.10 for CRISPR Therapeutics AG (CRSP) Traders Checklist Stock: CRISPR Therapeutics AG (CRSP) Somewhat Favorable Press Coverage Somewhat Unlikely to Affect CRISPR Therapeutics (CRSP) Stock Price |
